About Us
Ferring is a Swiss-based research
driven, specialty biopharmaceutical company active
in global markets. The company identifies, develops
and markets innovative products in the areas of
endocrinology, gastroenterology, infertility,
obstetrics, and urology. In recent years Ferring has
expanded beyond its traditional European base,
having now over 2500 employees worldwide and
operating subsidiaries in over 40 countries. The
U.S. company is based in Suffern, NY. To learn more
about Ferring or our products please visit
www.ferring.com.
Ferring R&D centers are located in San Diego (USA), Beer Tuvia (Israel) and Copenhagen
(Denmark). Ferring R&D skills and expertise
encompass peptide therapeutics, small molecule
mimetics at peptide/hormone receptors, protease
inhibitors and recombinant proteins.
Ferring Research Institute, Inc. (FRI, Inc.) was
established in San Diego in 1996 as Ferring's
peptide research center. FRI, Inc. is a fully
integrated target and drug discovery unit, primarily
focused on peptides, with capacity also in organic
chemistry and protein discovery. Research programs
have resulted in several clinical candidates,
including degarelix, a peptidic GnRH antagonist for
prostate cancer; barusiban, a peptidic oxytocin
antagonist for preterm labor; and FE 200665/CR665, a
peptidic kappa receptor agonist being developed by
Cara Therapeutics for the treatment of pain. A new
state of the art research facility is under
construction.